An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) to present at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, discussing mRNA cell therapy for autoimmune diseases.
Positive
None.
Negative
None.
GAITHERSBURG, Md.--(BUSINESS WIRE)--
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:00 p.m. ET.
A live webcast of the fireside chat is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the event will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
When will Cartesian Therapeutics, Inc. (RNAC) participate in the fireside chat at the 23rd Annual Needham Virtual Healthcare Conference?
Cartesian Therapeutics, Inc. (RNAC) is expected to participate in the fireside chat on Tuesday, April 9, 2024, at 3:00 p.m. ET.
What is the focus of Cartesian Therapeutics, Inc. (RNAC) in the fireside chat at the conference?
The focus of Cartesian Therapeutics, Inc. (RNAC) in the fireside chat is on mRNA cell therapy for autoimmune diseases.
Where can the live webcast of the fireside chat be accessed?
The live webcast of the fireside chat can be accessed in the Events section of Cartesian Therapeutics, Inc. (RNAC) website at www.cartesiantherapeutics.com.
Will there be an archived replay of the fireside chat available?
Yes, an archived replay of the fireside chat will be available for a time on Cartesian Therapeutics, Inc. (RNAC) website.
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
